AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9660521 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine (10 mg) once daily
Number of subjects: 24
Study 9660521 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (10 mg) once daily
Number of subjects: 24
Study 8533908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day stored platelets
Number of subjects: 25
Study 8533908 — intervention group
Group type: COMPARATOR
Intervention: 4-day stored platelets
Number of subjects: 25
Study 2039655 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Aminophylline
Number of subjects: 2
Study 2039655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6945041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (low cholesterol)
Number of subjects: 62
Study 6945041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (low cholesterol, high polyunsaturated fat)
Number of subjects: 62
Study 6945041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (low cholesterol, very low fat)
Number of subjects: 62
Study 31924736 — intervention group
Group type: EXPERIMENTAL
Intervention: RT/TMZ + Bevacizumab (BEV), n = 59
Number of subjects: 113
Study 31924736 — intervention group
Group type: COMPARATOR
Intervention: RT/TMZ, n = 54
Number of subjects: 113
Study 31924736 — intervention group
Group type: EXPERIMENTAL
Intervention: RT/TMZ + Bevacizumab (BEV) and RT/TMZ
Number of subjects: 113
Study 30124941 — intervention group
Group type: EXPERIMENTAL
Intervention: LESU200+XOI
Number of subjects: 0
Study 30124941 — intervention group
Group type: EXPERIMENTAL
Intervention: LESU400+XOI
Number of subjects: 0
Study 30124941 — intervention group
Group type: COMPARATOR
Intervention: XOI
Number of subjects: 0
Study 29658236 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil citrate (SC, n = 111)
Number of subjects: 222
Study 29658236 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 111)
Number of subjects: 222
Study 25999045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to obesity
Number of subjects: 0
Study 25999045 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exposure to heavier body weights
Number of subjects: 0
Study 25999045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to obesity in an online dating context
Number of subjects: 0
Study 23228813 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 190
Study 23228813 — intervention group
Group type: COMPARATOR
Intervention: 2009‐2010 TIV
Number of subjects: 190
Study 23228813 — intervention group
Group type: COMPARATOR
Intervention: 2008‐2009 TIV
Number of subjects: 190
Study 23228813 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (QIV, 2009‐2010 TIV, 2008‐2009 TIV)
Number of subjects: 190
Study 22097175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment after regression of proteinuria (Group B)
Number of subjects: 18
Study 22097175 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria (Group A)
Number of subjects: 18
Study 22097175 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 children, aged 8.5 ± 3.6 years)
Number of subjects: 18
Study 19485628 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Data Analysis (IDA)
Number of subjects: 0
Study 16982486 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (15 mg of zinc) once daily for prophylaxis, increased to 30 mg at onset of cold
Number of subjects: 200
Study 16982486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15125032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry exercise 3 times per week during dialysis at 40-50% maximal work capacity for 15 min during the first 3 hours of dialysis (EX)
Number of subjects: 13
Study 15125032 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 13
Study 15125032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry exercise (EX)
Number of subjects: 13
Study 10649149 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol plus norethindrone acetate (50 microg/d estradiol + 140/250/400 microg/d norethindrone acetate)
Number of subjects: 220
Study 10649149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 1341607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin delivery (1.0 mU/kg x min in 2 minute pulses every 13 minutes)
Number of subjects: 7
Study 1341607 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin delivery (0.15 mU/kg x min)
Number of subjects: 7
Study 1341607 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin delivery (0.20 mU/kg x min)
Number of subjects: 7
Study 6130244 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive management program (group A) using ultralente insulin as basal cover and soluble insulin at mealtimes, with more frequent clinic visits, closer dietary supervision, and home blood glucose monitoring
Number of subjects: 74
Study 6130244 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetic care (group U)
Number of subjects: 74
Study 6130244 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive management program (group A)
Number of subjects: 74
Study 30600270 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic sequencing
Number of subjects: 0
Study 30600270 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of genomic results for adult-onset conditions
Number of subjects: 0
Study 30859782 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 454
Study 30859782 — intervention group
Group type: COMPARATOR
Intervention: Physical Inactivity
Number of subjects: 454
Study 30859782 — intervention group
Group type: COMPARATOR
Intervention: Overweight/Obesity
Number of subjects: 454
Study 26927207 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-mm diameter fully covered self-expandable metallic stent (FCSEMS)
Number of subjects: 38
Study 23175678 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group representation (red or blue team)
Number of subjects: 0
Study 23204157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prem-8 (n = 38)
Number of subjects: 71
Study 23204157 — intervention group
Group type: COMPARATOR
Intervention: Control formula (n = 33)
Number of subjects: 71
Study 20492040 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus Tai Chi Chuan
Number of subjects: 163
Study 20492040 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 163
Study 20492040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 163
Study 20492040 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the three interventions (Education, Tai Chi Chuan, Education plus Tai Chi Chuan)
Number of subjects: 163
Study 20492040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163
Study 18555160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch fall prevention program (adapted from a British program)
Number of subjects: 21
Study 16000604 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 0
Study 16000604 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic chemotherapy
Number of subjects: 0
Study 16000604 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern radiotherapy techniques
Number of subjects: 0
Study 12850128 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol & Fluticasone (SM&FP) 50/250 microg bid
Number of subjects: 18
Study 10401443 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 4
Study 10401443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 4
Study 8914312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation Level (SL) at sound frequencies of 0.125, 0.5, 1, 2, 4, 6, and 8 kHz with levels set at 10, 20, 40, 60, and 80 dB.
Number of subjects: 0
Study 8914312 — intervention group
Group type: EXPERIMENTAL
Intervention: Loudness Level (LL) corresponding to SL at 1 kHz.
Number of subjects: 0
Study 1771386 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate (800 mg every 4 h)
Number of subjects: 100
Study 1771386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6745010 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lapyrium chloride (LC)
Number of subjects: 22
Study 6745010 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% lapyrium chloride (LC)
Number of subjects: 22
Study 6745010 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lapyrium chloride (LC)
Number of subjects: 22
Study 6745010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% sodium lauryl sulfate (SLS)
Number of subjects: 22
Study 6745010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium lauryl sulfate (SLS)
Number of subjects: 22
Study 31049566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Meal (HC, carbohydrates: 89% of energy)
Number of subjects: 21
Study 31049566 — intervention group
Group type: EXPERIMENTAL
Intervention: Normo-Carbohydrate Meal (NC, carbohydrates: 45% of energy)
Number of subjects: 21
Study 29500454 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (400 mg QD)
Number of subjects: 70
Study 29500454 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (10 mg QD)
Number of subjects: 70
Study 26305394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 180
Study 26305394 — intervention group
Group type: EXPERIMENTAL
Intervention: General Psychiatric Management (GPM)
Number of subjects: 180
Study 26305394 — intervention group
Group type: COMPARATOR
Intervention: BPD patients with comorbid PTSD
Number of subjects: 180
Study 26305394 — intervention group
Group type: COMPARATOR
Intervention: BPD patients without PTSD
Number of subjects: 180
Study 26305394 — intervention group
Group type: COMPARATOR
Intervention: Both groups (with and without PTSD)
Number of subjects: 180
Study 24777959 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical menthol application
Number of subjects: 10
Study 23805175 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 35
Study 23805175 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 35
Study 23805175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training (ATRT)
Number of subjects: 35
Study 21386723 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 45
Study 21386723 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 45
Study 21386723 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no stretching)
Number of subjects: 45
Study 18580879 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (0.3 mg/kg per os at the eighth and sixteenth hour)
Number of subjects: 26
Study 18580879 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 16533619 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 15
Study 16533619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12660520 — intervention group
Group type: EXPERIMENTAL
Intervention: HLAMatchmaker algorithm for identifying compatible donors
Number of subjects: 54
Study 12660520 — intervention group
Group type: EXPERIMENTAL
Intervention: HLAMatchmaker algorithm with additional antigens
Number of subjects: 54
Study 12660520 — intervention group
Group type: EXPERIMENTAL
Intervention: HLAMatchmaker algorithm considering one-triplet mismatches
Number of subjects: 54
Study 12660520 — intervention group
Group type: EXPERIMENTAL
Intervention: HLAMatchmaker algorithm considering two-triplet mismatches
Number of subjects: 54
Study 12660520 — intervention group
Group type: EXPERIMENTAL
Intervention: HLAMatchmaker algorithm with acceptable antigens identified by serum screens
Number of subjects: 54
Study 12660520 — intervention group
Group type: EXPERIMENTAL
Intervention: HLAMatchmaker algorithm with additional acceptable antigens
Number of subjects: 54
Study 10993856 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing at a base rate of 80 bpm
Number of subjects: 130
Study 10993856 — intervention group
Group type: COMPARATOR
Intervention: No pacing (control group, base rate 30 bpm)
Number of subjects: 130
Study 8707471 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (stressed students with LD)
Number of subjects: 45
Study 8707471 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonstressed students with LD)
Number of subjects: 45
Study 8707471 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (regular education students)
Number of subjects: 45
Study 1848385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Logiparin) 50 IU anti-Xa per kilo body weight once daily
Number of subjects: 190
Study 1848385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 190
Study 1848385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Logiparin)
Number of subjects: 190
Study 6860529 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 11
Study 6860529 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (300 mg)
Number of subjects: 11
Study 6860529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31471834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) therapy for more than 6 months
Number of subjects: 503
Study 31471834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) therapy for 6-12 months
Number of subjects: 503
Study 31471834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) therapy for 12-18 months
Number of subjects: 503
Study 31471834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) therapy for >24 months
Number of subjects: 503
Study 31471834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) therapy
Number of subjects: 503
Study 30383589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 2629
Study 30383589 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2629
Study 27965485 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 2 to 4°C cold saline irrigated during 5 minutes using EndoVac
Number of subjects: 75
Study 27965485 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of room temperature saline irrigated during 5 minutes using EndoVac
Number of subjects: 75
Study 27965485 — intervention group
Group type: COMPARATOR
Intervention: No additional irrigation applied (control)
Number of subjects: 75
Study 25214768 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (300 mg gabapentin)
Number of subjects: 37
Study 25214768 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (300 mg gabapentin)
Number of subjects: 37
Study 22246113 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber post (GFP) with 10 mm post space
Number of subjects: 75
Study 22246113 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber post (GFP) with 5 mm post space
Number of subjects: 75
Study 22246113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond fiber post (RFP) with 5 mm post space
Number of subjects: 75
Study 22246113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond fiber post (RFP) with 10 mm post space
Number of subjects: 75
Study 22246113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no post placed)
Number of subjects: 75
Study 20568096 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ
Number of subjects: 128
Study 20568096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17389704 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI 30 mg/d
Number of subjects: 240
Study 17389704 — intervention group
Group type: COMPARATOR
Intervention: PTU 300 mg/d
Number of subjects: 240
Study 17389704 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI 15 mg/d
Number of subjects: 240
Study 15799138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime diazepam
Number of subjects: 0
Study 15799138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12789956 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Kids' Power Toothbrush (D10) for 2 months
Number of subjects: 154
Study 12789956 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Kids' Power Toothbrush (D10)
Number of subjects: 154
Study 9583333 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal (PI) therapy
Number of subjects: 0
Study 9583333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) therapy
Number of subjects: 0
Study 9583333 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal style groups
Number of subjects: 0
Study 7617806 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300‐600 mg daily)
Number of subjects: 99
Study 7617806 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg daily)
Number of subjects: 99
Study 7617806 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (600 mg daily after doubling dosage for non-responders)
Number of subjects: 99
Study 7617806 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (40 mg daily)
Number of subjects: 99
Study 2571689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular bethanechol chloride infusion
Number of subjects: 49
Study 666936 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60
Study 666936 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60
Study 31352178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 30
Study 31352178 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 30
Study 29284427 — intervention group
Group type: EXPERIMENTAL
Intervention: DED patients
Number of subjects: 217
Study 25706090 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure + exercise (PE+E)
Number of subjects: 9
Study 25706090 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 9
Study 23571626 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated outbound telephone messaging
Number of subjects: 192
Study 23571626 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacies (no messaging)
Number of subjects: 192
Study 21470363 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic assessment in supine lying with arm at 90° abduction
Number of subjects: 12
Study 21470363 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic assessment in supine lying with arm at 45° abduction
Number of subjects: 12
Study 21470363 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic assessment in seated position with arm in scapular plane
Number of subjects: 12
Study 19030908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk supplemented with calcium (f-milk + Ca)
Number of subjects: 85
Study 19030908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk supplemented with calcium, inulin-type fructans and caseinphosphopeptides (f-milk + Ca + ITF + CPP)
Number of subjects: 85
Study 19030908 — intervention group
Group type: COMPARATOR
Intervention: Fermented milk (f-milk) without supplements
Number of subjects: 85
Study 16601534 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavioral intervention guided by the Transtheoretical Model and motivational interviewing
Number of subjects: 0
Study 16601534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14623523 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily
Number of subjects: 1276
Study 14623523 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 1276
Study 14623523 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (neoadjuvant)
Number of subjects: 1276
Study 14623523 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (neoadjuvant)
Number of subjects: 1276
Study 11101198 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil per day
Number of subjects: 114
Study 11101198 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mibefradil per day
Number of subjects: 114
Study 11101198 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg mibefradil per day
Number of subjects: 114
Study 11101198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during run-in period)
Number of subjects: 114
Study 8992903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg IV 30 min before anaesthesia
Number of subjects: 20
Study 8992903 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 1303408 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional management and 4 sessions of hyperbaric oxygen therapy
Number of subjects: 30
Study 1303408 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 30
Study 4027121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 12
Study 4027121 — intervention group
Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 12
Study 4027121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4027121 — intervention group
Group type: COMPARATOR
Intervention: Mebhydrolin
Number of subjects: 12
Study 31392496 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary internal fixation with unreamed interlocking nail
Number of subjects: 29
Study 31392496 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary internal fixation with plate
Number of subjects: 29
Study 31392496 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary internal fixation
Number of subjects: 29
Study 29898848 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg bid or 2.5 mg bid if combined with antiplatelet therapy)
Number of subjects: 0
Study 29898848 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC Group) including VKA therapy or antiplatelet therapy (single or dual)
Number of subjects: 0